Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Overview

• Rare, aggressive hematologic malignancy derived from precursors of plasmacytoid dendritic cells; a distinct WHO entity (historically called blastic NK-cell lymphoma or CD4+/CD56+ hematodermic neoplasm).
• Predominantly older adults, male predominance.
• Presentation: most commonly cutaneous lesions first (violaceous/bruise-like plaques, nodules, or patches), followed by (or concurrent with) bone marrow and leukemic involvement, lymphadenopathy, and cytopenias. It behaves as a systemic disease even when it appears skin-limited.

Immunophenotype

• Characteristic markers: CD123 (IL-3 receptor alpha, bright and uniform), CD4+, CD56+, TCL1+, plus plasmacytoid dendritic cell markers CD303 (BDCA-2) and CD304 (BDCA-4).
• TdT positive in ~one third of cases; often CD68 dot-like positivity.
• Negative for lineage-specific markers: myeloperoxidase (MPO), CD3, CD19/CD20, and other B/T/myeloid-defining antigens, which helps exclude AML and lymphoblastic leukemia/lymphoma.
• The CD123/CD4/CD56/TCL1 profile with negative lineage markers is the diagnostic signature and the rationale for CD123-targeted therapy.

Treatment Options

• Tagraxofusp-ersz (preferred), a CD123-directed therapy (see below).
• Pivekimab sunirine-pvzy (Decnupaz): CD123-directed antibody and alkylating agent conjugate, FDA-approved May 27, 2026 for adults with BPDCN (CADENZA: CR/CRc 69.7% treatment-naive, 15.7% R/R); 0.045 mg/kg IV every 3 weeks; boxed warning for hepatotoxicity including veno-occlusive disease.
• AML-type induction (standard-dose cytarabine plus an anthracycline, "7+3").
• ALL-type induction (hyper-CVAD).
• Lymphoma-type regimens (CHOP-based).
• Allogeneic (or, in selected cases, autologous) stem-cell transplant consolidation in first remission is a key goal, as durable remissions with chemotherapy alone are uncommon.

Tagraxofusp (SL-401)

• Mechanism: an anti-CD123-directed fusion protein composed of human interleukin-3 (IL-3) fused to a truncated diphtheria toxin (DT). After binding CD123, it is internalized, inhibiting protein synthesis and causing cell death.
• Efficacy:
  • Initial SL-401 study (mixed untreated and relapsed): 12.5 mcg/kg over 15 min daily for up to 5 doses; 7 of 9 evaluable responded (78%), median DOR ~5 months. Approved tagraxofusp dose is 12 mcg/kg IV days 1 to 5 every 21 days.
  • Untreated or relapsed BPDCN: 7 or 12 mcg/kg on days 1 to 5 of each 21-day cycle; first-line ORR 90%, R/R ORR 67% (median OS ~8.5 months in the R/R cohort). Most responses were high quality (CR/CRc); in the first-line cohort, 45% (13 of 29) were bridged to stem-cell transplant in remission (34% of the cohort allogeneic, 10% autologous).
• Toxicity: fever, chills, hypotension, edema, hypoalbuminemia, thrombocytopenia, and transaminase elevation (generally transient). The most serious adverse effect is capillary leak syndrome (CLS), which can occur during the first cycle and is life-threatening.
  • A decrease in serum albumin during the first days of treatment is the most consistent predictor of CLS.
  • Require a baseline serum albumin of ≥ 3.2 g/dL to start treatment; replace albumin to keep it ≥ 3.5 g/dL.
  • Management of CLS: delay or withhold further tagraxofusp doses, administer IV albumin per pre-specified thresholds, give glucocorticoids, and manage volume status closely.

Chemotherapy & Transplant Data

• In a study comparing AML-type vs ALL-type induction, the overall CR rate was 41%. Patients receiving ALL/lymphoma-type chemotherapy had longer OS than AML-type (12.3 vs 7.1 months; P = 0.02).
• Patients who received a transplant had significantly higher OS than non-transplanted patients (22.7 vs 7.1 months; P = 0.03), reinforcing transplant consolidation in first remission.

High-Yield Pearls

• CD123 + CD4 + CD56 + TCL1 with negative lineage markers (MPO-negative, CD3-negative, CD19-negative) = BPDCN.
• Cutaneous, bruise-like lesions are the classic presentation; assume systemic disease with marrow/leukemic spread.
• Tagraxofusp (anti-CD123 fusion toxin) is the preferred targeted therapy; watch for capillary leak syndrome and follow serum albumin (start if ≥ 3.2, keep ≥ 3.5 g/dL).
• ALL-type induction outperformed AML-type; allo-HCT in CR1 gives the best durable outcomes.